98%
921
2 minutes
20
Osteosarcoma (OS) and extraskeletal osteosarcoma (EOS) in dogs exhibit histological similarities but differ in anatomical origin, which poses a challenge to diagnostic accuracy. We adopted a marker-first strategy to enhance molecular classification by selecting RUNX2, KPNA2, and SATB2, three validated immunohistochemical (IHC) markers, as primary targets. Bioinformatic screening identified the miR-30 family as the only miRNA group predicted to coordinately regulate RUNX2, KPNA2, and SATB2, justifying its prioritization for expression analysis. RT-qPCR on FFPE tissues from 14 OS, 19 EOS, and 10 healthy controls revealed that miR-30a was significantly downregulated in OS and inversely correlated with RUNX2 nuclear expression, confirmed by IHC. MiR-30e also showed high diagnostic accuracy, while miR-30b and miR-30c distinguished EOS from OS. Non-seed interaction modeling (i.e., outside the canonical "seed" region, spanning nucleotides 2-8 of the miRNA) suggested divergent regulatory affinities within the PI3K/AKT/RUNX2 axis among miR-30 family members. MiR-30a and miR-30e exhibited the highest diagnostic power (LR 7.7 and 6.8, respectively), supporting their role as biomarkers. These results highlight a miR-30-centered regulatory axis with relevance for diagnosis and molecular stratification of canine osteogenic tumors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384767 | PMC |
http://dx.doi.org/10.3390/cells14161279 | DOI Listing |
J Clin Orthop Trauma
November 2025
Department of Medical Oncology, All India Institute of Medical Sciences, Rishikesh, India.
Background: High-grade osteosarcoma is the most prevalent primary malignant bone tumor in children and adolescents. Despite advancements in chemotherapy and surgical techniques, survival rates have stagnated, particularly in patients presenting with metastases or poor chemotherapeutic response. This study aims to evaluate survival outcomes and identify prognostic factors influencing overall survival in pediatric osteosarcoma patients treated at a tertiary care center.
View Article and Find Full Text PDFOral Dis
August 2025
Department of Oral Pathology, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, China.
Objectives: We aimed to investigate genotype-phenotype correlations, variant prevalence, and prognostic factors in a Chinese cohort with craniofacial FD/MAS.
Methods: A retrospective study of 93 histologically confirmed FD/MAS cases (2003-2024) analyzed GNAS mutations via direct sequencing. Clinical data, including disease onset, lesion activity (active vs.
Cells
August 2025
Department of Veterinary Medicine, Università degli Studi di Perugia, 06126 Perugia, Italy.
Osteosarcoma (OS) and extraskeletal osteosarcoma (EOS) in dogs exhibit histological similarities but differ in anatomical origin, which poses a challenge to diagnostic accuracy. We adopted a marker-first strategy to enhance molecular classification by selecting RUNX2, KPNA2, and SATB2, three validated immunohistochemical (IHC) markers, as primary targets. Bioinformatic screening identified the miR-30 family as the only miRNA group predicted to coordinately regulate RUNX2, KPNA2, and SATB2, justifying its prioritization for expression analysis.
View Article and Find Full Text PDFIndian J Cancer
April 2025
Department of Surgery, Mahatma Gandhi Institute of Medical Science, Sewagram, Wardha, Maharashtra, India.
Here, we present a rare case of a 74-year-old woman with intermittent haematuria for 6 months. Computed tomography urography showed an ill-defined heterogeneously enhancing soft tissue lesion near the neck of the bladder. The patient was advised of radical cystectomy with an ileal conduit for which the patient was unwilling.
View Article and Find Full Text PDFDiagn Pathol
July 2025
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Background: Ewing's sarcoma (ES), first described by Ewing in 1921, is a highly malignant small blue round cell tumor that arises in bone or extraskeletal soft tissues. It predominantly affects patients aged 10 to 30 years. Approximately 12% of cases involve solid organs, often presenting as rapidly growing masses in deep soft tissues.
View Article and Find Full Text PDF